Copenhagen, Denmark
Copenhagen, Denmark

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsvaerd, Denmark, with production facilities in seven countries, and affiliates or offices in 75 countries.Novo Nordisk manufactures and markets pharmaceutical products and services. Key products include diabetes care medications and devices. Novo Nordisk is also involved with haemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza.Novo Nordisk employs more than 40,000 people globally, and marketed its products in 180 countries. It is the largest publicly traded company in the Nordic countries by market capitalization. The corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt.Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations .The company was ranked 25th among 100 best companies to work for in 2010 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights while spin-off company Novozymes was named fourth. Novo Nordisk was ranked 72nd on “Fortune’s 100 Best Companies to Work For®” list within the U.S. state of New Jersey as of January 2014. Wikipedia.


Time filter

Source Type

Patent
Novo Nordisk AS | Date: 2016-11-18

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.


Patent
Novo Nordisk AS | Date: 2016-11-02

The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.


Patent
Novo Nordisk AS and Sanquin Blood Supply Foundation | Date: 2016-11-18

The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.


Patent
Novo Nordisk AS | Date: 2016-09-12

The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.


Patent
Novo Nordisk AS | Date: 2016-11-08

The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K^(27), and the second K residue is designated K^(T); which derivative comprises two albumin binding moieties attached to K^(27 )and K^(T), respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC(CH_(2))_(x)CO and HOOCC_(6)H_(4)O(CH_(2))_(y)CO; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula NH(CH_(2))_(2)(O(CH_(2))_(2))_(k)O(CH_(2))_(n)CO, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel GLP-1 analogues. The derivatives are suitable for oral administration.


Patent
Novo Nordisk AS | Date: 2017-04-12

An add-on logging device (100, 300) mounted to a drug delivery device is turned on when the cap is removed. After a given amount of time in inactivity the sensor means of the add-on device is turned off automatically to save energy. If the user takes a dose of drug this is not detected as the add-on device is only turned on when the cap is removed. According to the present invention a warning message is provided when the cap is re-mounted after the sensor means has been turned off automatically, the warning message indicating to a user that an expelled dose may not have been detected.


Patent
Novo Nordisk AS | Date: 2017-03-08

A protein purification process with virus inactivation or removal uses caprylic acid (octanoic acid) at acidic pH. The method comprises caprylic acid treatment as part of the chromatographic step so as to perform viral inactivation without a discontinuous process and without the requirement of attention by personnel, particularly when the pH adjustment of the eluate is performed automatically by eluting into buffer. The method of the invention further results in mycoplasmas being inactivated, and reduced impurities like Host Cell Protein (HCP).


Patent
Novo Nordisk AS | Date: 2017-01-25

The present invention relates to an injection device for delivering set doses of a liquid drug to a user. The injection device has a scale drum for displaying the set dose, which scale drum is helically guided in a housing. The scale drum is thus rotational in relation to the housing between a zero position and a set position for displaying the set dose. Further, a needle cannula secured to a hub is mounted in an axially movable manner. The axial movement of the hub is generated by a spring. A blocking mechanism interacting between the scale drum and hub controls the axial movement of the hub such that the needle cannula automatically retracts from the skin of a user in response to the scale drum reaching the zero position.


Patent
Novo Nordisk AS | Date: 2016-12-28

Telescopic drive assembly comprising a rotatable threaded drive member, an outer tube assembly arranged axially moveable relative to the drive member but non-rotational relative to a frame and comprising a nut portion in threaded engagement with the drive member, a transmitter tube with an outer thread, and a drive tube in threaded engagement with the transmitter tube outer thread. The outer tube assembly comprises a tube guide member coupled to the nut portion via an Oldham coupling.


Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a longer half-life was developed without changing the protein structure. FVIII-polyethylene glycol (PEG) conjugates were prepared using an enzymatic process coupling PEG (ranging from 10 to 80 kDa) selectively to a unique O-linked glycan in the FVIII B-domain. Binding to von Willebrand factor (VWF) was maintained for all conjugates. Upon cleavage by thrombin, the B-domain and the associated PEG were released, generating activated FVIII (FVIIIa) with the same primary structure and specific activity as native FVIIIa. In both FVIII- and VWF-deficient mice, the half-life was found to increase with the size of PEG. In vivo potency and efficacy of FVIII conjugated with a 40-kDa PEG (N8-GP) and unmodified FVIII were not different. N8-GP had a longer duration of effect in FVIII-deficient mouse models, approximately a twofold prolonged half-life in mice, rabbits, and cynomolgus monkeys; however, the prolongation was less pronounced in rats. Binding capacity of N8-GP on human monocyte-derived dendritic cells was reduced compared with unmodified FVIII, resulting in several-fold reduced cellular uptake. In conclusion, N8-GP has the potential to offer efficacious prevention and treatment of bleeds in hemophilia A at reduced dosing frequency.

Loading Novo Nordisk AS collaborators
Loading Novo Nordisk AS collaborators